Literature DB >> 18222149

EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer.

Vincent A Miller1.   

Abstract

OBJECTIVES: To discuss selected molecular targets and new clinical variables that can serve as both predictive and prognostic markers for outcome in patients with non-small cell lung cancer (NSCLC) treated with EGFR-TKIs. DATA SOURCES: Research and journal articles.
CONCLUSION: In the near future, treatment for NSCLC will rely ever increasingly on molecular targets rather than empirically chosen cytotoxic chemotherapy for some patients. This will improve outcomes for patients with NSCLC. IMPLICATIONS FOR NURSING PRACTICE: An understanding of the molecular targets and clinical variables that are predictive and prognostic of outcome in NSCLC will help nurses better care for these patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18222149     DOI: 10.1016/j.soncn.2007.11.009

Source DB:  PubMed          Journal:  Semin Oncol Nurs        ISSN: 0749-2081            Impact factor:   2.315


  5 in total

1.  Src family kinase inhibitor PP2 efficiently inhibits cervical cancer cell proliferation through down-regulating phospho-Src-Y416 and phospho-EGFR-Y1173.

Authors:  Lu Kong; Zhihong Deng; Haiying Shen; Yuxiang Zhang
Journal:  Mol Cell Biochem       Date:  2010-11-04       Impact factor: 3.396

2.  Evaluation of PCR-HRM, RFLP, and direct sequencing as simple and cost-effective methods to detect common EGFR mutations in plasma cell-free DNA of non-small cell lung cancer patients.

Authors:  Jamal Zaini; Elisna Syahruddin; Muhammad Yunus; Sita Laksmi Andarini; Achmad Hudoyo; Najmiatul Masykura; Refniwita Yasril; Asep Ridwanuloh; Heriawaty Hidajat; Fariz Nurwidya; Sony Suharsono; Ahmad R H Utomo
Journal:  Cancer Rep (Hoboken)       Date:  2019-02-03

3.  Evaluation of PTEN and Mcl-1 expressions in NSCLC expressing wild-type or mutated EGFR.

Authors:  Zafer Cetin; Gulay Ozbilim; Abdullah Erdogan; Guven Luleci; Sibel Berker Karauzum
Journal:  Med Oncol       Date:  2009-09-10       Impact factor: 3.064

4.  Histologic Grade Is Predictive of Incidence of Epidermal Growth Factor Receptor Mutations in Metastatic Lung Adenocarcinoma.

Authors:  Michelle Levy; Liisa Lyon; Erika Barbero; John Wong; Marie Suga; Danny Sam; Minggui Pan
Journal:  Med Sci (Basel)       Date:  2017-12-11

5.  Independent of ErbB1 gene copy number, EGF stimulates migration but is not associated with cell proliferation in non-small cell lung cancer.

Authors:  Camila Lauand; Paula Rezende-Teixeira; Beatriz Araújo Cortez; Evandro Luís de Oliveira Niero; Gláucia Maria Machado-Santelli
Journal:  Cancer Cell Int       Date:  2013-04-30       Impact factor: 5.722

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.